Identification, synthesis and structure assignment of two impurities of Erlotinib, a drug used for the treatment of some types of cancer. | Zendy

María Guadalupe Morales-Vilchis | Zendy; Patricia FloresSánchez | Zendy; Jaime Escalante | Zendy

Open Access

Identification, synthesis and structure assignment of two impurities of Erlotinib, a drug used for the treatment of some types of cancer.

Author(s) -

María Guadalupe Morales-Vilchis,

Patricia FloresSánchez,

Jaime Escalante

Publication year - 2019

Publication title -

journal of the mexican chemical society

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.172

H-Index - 22

ISSN - 2594-0317

DOI - 10.29356/jmcs.v63i1.714

Subject(s) - erlotinib , impurity , drug , identification (biology) , chemistry , combinatorial chemistry , stereochemistry , organic chemistry , pharmacology , biochemistry , medicine , epidermal growth factor receptor , biology , botany , receptor

In the synthesis and industrial production of Erlotinib, the formation of organic impurities has been detected, so the identification and control of these is a critical point within the process. Standards for the consumption of pharmaceutical products are well established for active substances. In this sense, the synthesis and unequivocal identification of two impurities of Erlotinib as structural isomers was developed in the present study. The structural characterization of both isomers was confirmed by 1H and 13C-NMR as well as by their X-ray diffraction study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research